Supplementary Table 2.
General characteristics of the included studies for remdesivir
| Name of first author, Year | Study site | Population€ | Study Design | Intervention | Comparator | Primary Outcome measured | Primary Outcome: how it was measured | *Sample size in intervention | *Sample size in comparator | Outcome in intervention | Outcome in control |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Beigel J H et al., 2020 | North America, Europe, and Asia | Adults with Covid-19 (moderate and severe) | Double-blind, randomized, placebo-controlled trial | Remdesivir | Placebo | Clinical improvement | Median time to recovery (days) measured on a ordinal scale | 538 | 521 | 11 days | 15 days |
| Spinner CD et al | United States, Europe and Asia | Patients > 12 years of age With Moderate COVID-19 | Open label randomized, controlled trial | a. Remdesivir for 5 days b. Remdesivir for 10 days | Standard Care | Clinical improvement | Difference in clinical status distribution vs standard care, odds ratio (95% CI) | a. 191 b. 193 | 200 | a. 1.65 (1.09-2.48) b. NA | 1 [Reference] |
| Wang Y et al., 2020 | China | Adults with severe covid 19 | Double-blind, randomized, placebo-controlled trial | Remdesivir | Placebo | Clinical improvement | Median Time to clinical improvement measured on ordinal scale | 158 | 78 | 21 days | 23 days |
| Goldman JD et al., 2020 | North America, Europe, and in Asia | Patient >12 years of age with Severe Covid-19 | Open label randomized, controlled trial | Remdesivir for 5 days | Remdesivir for 10 days | Clinical improvement | Clinical improvement, assessed on ordinal scale on day 14 | 200 | 197 | 65% | 54% |
| Grein J et al., 2020 | United States, Europe or Canada, and Japan | Patient with Severe Covid-19 | Single arm prospective study | Remdesivir | None | #Clinical improvement | Clinical improvement on the ordinal scale or live discharge at day 28 | 53 | - | 84% | - |
| Antinori S, et al., 2020 | Italy | Adults with severe Covid-19 | Single arm prospective study | Remdesivir | None | #Clinical improvement | Change in hospitalization status based on a ordinal scale at day 28 | 35 | - | 62.80% | - |
€All of these were hospitalized patients. #There was no specified primary end point. *Sample size is according to number of subjects included in data analysis. NA - Odds ratio can not be determined as proportional odds assumption was not met